{"id":"W2831987875","doi":"10.1016/j.jaad.2018.06.057","title":"Psoriasis: Which therapy for which patient","year":2018,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":361,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Johnson and Johnson; Janssen Biotech; MedImmune; Valeant Pharmaceuticals International; AbbVie; Boehringer Ingelheim; AstraZeneca; Novartis; Pfizer","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Disease; Malignancy; Intensive care medicine; Food and drug administration; Quality of life (healthcare); Dermatology; Internal medicine; Pharmacology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03994703862697566,"score_gpt":0.3288898187731032,"score_spread":0.2889427801461276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}